JW Pharmaceutical Corp (001065) — Cash Flow-to-Debt Ratio
JW Pharmaceutical Corp (001065) has a Cash Flow-to-Debt Ratio of 0.18x as of September 2025, meaning its operating cash flow of ₩46.92 Billion could theoretically repay 0% of its total liabilities (₩257.46 Billion) in one year. See 001065 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
JW Pharmaceutical Corp Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for JW Pharmaceutical Corp across 11 annual periods. Also explore JW Pharmaceutical Corp (001065) equity growth momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for JW Pharmaceutical Corp (2014–2024)
Year-by-year debt coverage analysis for JW Pharmaceutical Corp. For market capitalisation and broader financial context, see how much is JW Pharmaceutical Corp worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.29x | ₩79.39 Billion | ₩275.11 Billion | ▲ +25.7% |
| 2023 | 0.23x | ₩87.16 Billion | ₩379.60 Billion | ▲ +62.7% |
| 2022 | 0.14x | ₩56.76 Billion | ₩402.21 Billion | ▲ +246.1% |
| 2021 | 0.04x | ₩18.12 Billion | ₩444.51 Billion | ▼ -77.9% |
| 2020 | 0.18x | ₩63.05 Billion | ₩341.62 Billion | ▲ +14.0% |
| 2019 | 0.16x | ₩55.53 Billion | ₩343.12 Billion | ▲ +3.6% |
| 2018 | 0.16x | ₩52.11 Billion | ₩333.68 Billion | ▲ +68.1% |
| 2017 | 0.09x | ₩33.45 Billion | ₩360.10 Billion | ▲ +416.6% |
| 2016 | 0.02x | ₩6.74 Billion | ₩374.76 Billion | ▲ +267.1% |
| 2015 | -0.01x | ₩-4.17 Billion | ₩388.07 Billion | ▼ -154.6% |
| 2014 | 0.02x | ₩7.28 Billion | ₩369.22 Billion | — |